



## LMC Communique January 2025 – Calderdale LES Update

The LMC Executive concluded negotiations with the ICB on many of our existing Enhanced Service specifications this month. These outcomes were fully discussed at this month's full committee meeting where a full support was given to the positive outcomes and a proposed LMC position for practices. The headline outcomes include:

- An average uplift across the services of 6.75%, a significant outcome compared to the 2.8% initial position.
- The dismantling of the 'basket' LES for Treatment Room, which has now been broken down into individual service specifications. Calderdale is now one of the only areas nationally that does not have any 'basket' agreements moving forward.
- On key specifications, an agreement to review activity levels assumed by the commissioners, as a basis for funding at the end of 12 months. This ensures that future funding will reflect actual levels of activity based on a negotiated unit cost.
- A significant improvement to the level of investment per head of population in general practice enhanced services that compares positively with other places in West Yorkshire.

Over the past three years the LMC, through positive relationships with our ICB has ensured increasing levels of funding direct to practices has continued. During this period, there has been an additional **17.8p/patient (£3.5m)** invested directly to our practices across Calderdale through Enhanced Services and additional schemes. This has included a 120% increase in phlebotomy funding, a 59% increase in shared care for amber drugs and an average of 8.9% across the remaining Enhanced Services.

The following table confirms the outcomes agreed across five of our existing Enhanced Services, plus a new activity-based service. Please also note the following:

- The Shared Care Enhanced Service is currently under negotiation at West Yorkshire. Our existing agreement will remain in place until the process is completed. The LMC position is to continue with our existing arrangement until those negotiations are complete and a clear position on a new service can be shared with our practices.
- The Diabetes Level 3 ES is currently under review, and we will advise practices following the conclusion of this process.

**(RAG Rating: Green=financially viable, Amber=break even, Red=financial loss)**

LES Specification and Funding Offer	RAG Rating / LMC Position
<p><b><u>Community Phlebotomy</u></b></p> <p>Service specification agreed with LMC Funding</p> <p><b>£2.20 per patient/annum (9.2% uplift)</b></p>	<p><b>LMC support this agreement as this offer provides financial viability for practices at the anticipated level of activity.</b></p> <p><b>There will be a review with the ICB on activity levels at the end of year 1 to consider if funding requires re-negotiation.</b></p>

<p><b><u>Wound Management (formerly the Treatment Room)</u></b></p> <p>New specification to be finalised once a clear system wide wound management pathway agreed. This will specify level 1 wounds, referral processes into more complex and clarity on not including home visits.</p> <p><u>Funding</u></p> <p><b>£1.10 per patient/annum (3.8% uplift)</b></p>	<p>The LMC support the financial cost used as a basis for this service with two caveats:</p> <ol style="list-style-type: none"> <li>1. Activity levels for all wound dressings completed in general practice across the whole of Calderdale does not exceed 20,000</li> <li>2. A full data review at the end of year 1 and to re-negotiate the rate if activity significantly beyond agreed level.</li> </ol>
<p><b><u>Ear Irrigation/micro suction</u></b></p> <p>New specification to be agreed now this is removed from Treatment Room Les. The initial service provision will be 6 months.</p> <p><u>Funding</u></p> <p><b>£16.68 per activity</b></p>	<p>LMC support this as financially viable.</p> <p>Assurance has been given that any future provision of this service will be fully discussed with the Primary Care Strategy Group and the LMC.</p>
<p><b><u>Anticoagulation Monitoring</u></b></p> <p>Service specification agreed with LMC</p> <p><u>Funding</u></p> <p><b>£12.16 per patient (13% uplift)</b></p>	<p>LMC support this as financially viable.</p>
<p><b><u>Gonadorelin Analogues</u></b></p> <p>Service specification agreed with LMC</p> <p><u>Funding</u></p> <p><b>£45.12 (2025 contract uplift to be notified)</b></p>	<p>LMC support this as financially viable</p>
<p><b><u>Ring Pessary Insertion</u></b></p> <p>Service specification agreed with LMC</p> <p><u>Funding</u></p> <p><b>£32.68 (5% uplift)</b></p>	<p>Additional fully funded ICB Offer: Training provision for 50 Practice Nurses at £95/head.</p> <p>LMC have an advisory position on this offer. The funding is breakeven where the service is offered by nursing. For practices that offer through a GP there will be a financial loss.</p>